发明名称 |
ST6GAL I MEDIATED MODULATION OF HEMATOPOIESIS |
摘要 |
Provided are methods for reducing haematocytes in an individual. The method involve administering to an individual a composition that contains recombinant a2,6-sialyltransferase (ST6Gal I). The method is suitable for prophylaxis and therapy of a condition that is positively correlated with undesirable hematopoiesis. Such conditions include autoimmune diseases, transplantation rejection, blood cancers and allergic reactions and inflammations. The invention also provides a pharmaceutical preparation that contains recombinant ST6Gal I and which is suitable for administration to an individual to reduce haematocytes in the individual, and a pharmaceutically acceptable carrier. |
申请公布号 |
US2014242058(A1) |
申请公布日期 |
2014.08.28 |
申请号 |
US201214128642 |
申请日期 |
2012.06.25 |
申请人 |
Lau Joseph;Kenari Mehrab Nasiri |
发明人 |
Lau Joseph;Kenari Mehrab Nasiri |
分类号 |
A61K38/45 |
主分类号 |
A61K38/45 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for reducing haematocytes in an individual comprising administering to the individual a composition comprising recombinant a2,6-sialyltransferase (ST6Gal I), wherein the administration results in a reduction of haematocytes in the individual. |
地址 |
Hamburg NY US |